Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, AbbVie will pay DJS. DJS shareholders remain eligible for potential additional payments upon the achievement of certain development milestones related to the success of the DJS-002 program.
Lead Product(s): DJS-002
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: DJS-002
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: Undisclosed Upfront Cash: $255.0 million
Deal Type: Acquisition October 20, 2022